Improvements in fatigue are associated with early treatment with darbepoetin alfa every 3 weeks in anemic patients receiving chemotherapy

Journal of Supportive Oncology

Volumn 3, Issue 2 SUPPL. 1, 2005, Pages 14-15

  Charu, Veena ^a   Saidman, Bruce ^a   Ben Jacob, Ali ^a   Justice, Glen R ^a   Maniam, Ajit S ^a   Rearden, Timothy ^a   Tomita, Dianne ^a   Rossi, Greg ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; CANCER; CANCER CHEMOTHERAPY; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; PARALLEL DESIGN; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 15944408326     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Charu V, Saidman B, Ben-Jacob A, et al. Improvements in fatigue are associated with early treatment with every-3-week (Q3W) darbepoetin alfa (DA) treatment in anemic patients (pts) receiving chemotherapy (Ctx). Paper presented at the 46th Annual Meeting of the American Society of Hematology; December 4-7, 2004; San Diego, Calif. Abstract 233.